FDA Grants Accelerated Approval to GSK's Nelkarmi for ALK-Positive Lung Cancer

11/17/2026
Impact: 75
Healthcare

The FDA granted accelerated approval to GSK’s Nelkarmi for patients with ALK-positive lung cancer, allowing its immediate use in this population. The approval expands GSK’s oncology portfolio; the article reports no financial figures or stock-market impact.

AI summary, not financial advice

Share: